title: Progress and Hurdles for Follow-on Biologics.
authors.affiliation: From the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston.
authors.forename: Ameet
authors.initials: A
authors.lastname: Sarpatwari
authors.forename: Jerry
authors.initials: J
authors.lastname: Avorn
authors.forename: Aaron S
authors.initials: AS
authors.lastname: Kesselheim
mesh_terms: D001688:Biological Products; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry; D016568:Drugs, Generic / Q000191:economics; D033161:Government Regulation; D011306:Prescription Fees; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001688:Biological Products; D016568:Drugs, Generic